 I'm Kinsey Grant and I'm here with Andrew Ritter, the president of Ritter Pharmaceuticals. So Mr. Ritter, can you tell me a little bit more about what your company does? Sure, so Ritter Pharmaceuticals, we're developing treatments for digestive diseases. And our main treatment currently in development is for lactose and tolerance. We're developing the first FDA approved drug to treat this condition. So what is this treatment entail? How does it work and why is it important for Ritter to take on here? So first of all, lactose and tolerance, over 40 million Americans suffer from this condition. 9 million have marked severe symptoms. There's not much these individuals can do for their lactose and tolerance. They simply can avoid dairy products or suffer the consequences. Our product is a one-time treatment where you take it for 30 days and then afterwards you can tolerate dairy products symptom-free. Alright, and so what's the timeline looking like here for this treatment to reach the consumer? Do you have any indication on that? So we're currently in our phase 3 clinical studies for the product, for the therapeutic and we just are about to launch that phase 3 study in the first half of 2018 coming up. Alright, thank you so much for joining us today. Thanks.